<DOC>
	<DOCNO>NCT00843921</DOCNO>
	<brief_summary>This study base hypothesis new drug N-carbamylglutamate ( Carbaglu® ) enhance ability liver dispose toxic ammonia accumulate several metabolic disease include urea cycle disorder organic acid disorder .</brief_summary>
	<brief_title>N-Carbamylglutamate ( Carbaglu ) In The Treatment Of Hyperammonemia</brief_title>
	<detailed_description>Hyperammonemia associate several rare inherit disorder frequently cause mental retardation , developmental disability death . The overall goal study investigate short-term efficacy safety orphan drug , N-Carbamyl-L-glutamate ( Carbaglu® , abbreviate NCG ) , treatment hyperammonemia rare inherited disorder : carbamyl phosphate synthetase I ( CPSI ) deficiency , NAGS deficiency , ornithine transcarbamylase ( OTC ) deficiency , propionic acidemia ( PA ) methylmalonic acidemia ( MMA ) . The primary aim : 1 . To investigate whether 3-day treatment NCG improve restore ureagenesis capacity patient NAGS , CPSI OTC deficiency use surrogate marker : [ 13C ] label incorporation urea plasma level ammonia , urea glutamine . In addition , determine whether treatment NCG OTC deficiency increase production nitrogen contain intermediate , orotic acid , mechanism eliminate nitrogen lieu urea . 2 . To investigate whether ureagenesis capacity deficient patient PA MMA whether 3-day treatment NCG improve restore ureagenesis capacity patient . 3 . To evaluate safety short-term ( 3-day ) treatment NCG patient use clinical laboratory parameter . The hypothesis ureagenesis capacity evidence [ 13C ] incorporation urea deficient five disorder treatment NCG improve restore ureagenesis patient affect . The study conduct General Clinical Research Centers ( GCRC ) Children 's National Medical Center , Washington , D.C. Children 's Hospital Philadelphia . Patients ( 1 day 70 year age ) five disorder eligible study . They test short-term trial use surrogate marker ( incorporation [ 13C ] label Na-acetate urea , plasma level ammonia , urea glutamine ) immediately follow 3 day treatment NCG . The patient also evaluate short-term safety NCG use clinical laboratory parameter . The result study provide important efficacy data , help bring Carbaglu® ) US market benefit patient orphan disease find responsive NCG trial .</detailed_description>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Hyperammonemia</mesh_term>
	<criteria>1 . Between 1 day 70 year age 2 . Viable neonate , neonate uncertain viability exclude Diagnosed one follow five inborn error metabolism : NAGS , CPSI , PA , MMA , OTC deficiency . 3 . Diagnostic requirement : NAGS deficiency Identification pathogenic mutation and/or decrease ( &lt; 20 % control ) NAGS enzyme activity liver CPSI deficiency decrease ( &lt; 20 % control ) CPSI enzyme activity liver deficiency liver CPSI presence normal substantial activity OTC ( Tuchman et al 1980 ) and/or molecular confirmation deleterious mutation ( Summary et al 2003 ) . High level clinical suspicion NAGS CPSI deficiency Failure meet diagnostic criterion either NAGS CPSI deficiency list , : 1 . Recurrent hyperammonemic episode ( NH3 &gt; 70umol/l ) elevate plasma glutamine ( &gt; /= 800umol/l ) 2 . Urinary orotate level within normal limit ( &lt; /= 5 umol/mmol urine creatinine ) 3 . Absence argininosuccinic acid blood urine 4 . Low normal level citrulline ( &lt; /=92umol/l ) arginine ( &lt; /= 179 umol/l ) ornithine ( &lt; /=159umol/l ) within normal limit blood OTC deficiency Identification pathogenic mutation and/orpedigree analysis consistent familial hyperammonemia segregate xlinked semidominant pattern and/or &lt; 20 % control OTC activity liver and/or elevate urinary orotate ( &gt; 20 % umol/mmol creatinine ) allopurinol challenge test PA MMA diagnostic urine organic acid analysis confirmation absence responsiveness biotin vitamin B12 respectively . Subjects acutely ill day study Pregnant female documentation negative pregnancy test within week prior test require female 12 year old , unless menstrual period week circumstance preclude pregnancy ( e.g . hysterectomy , menopause ) Subjects hyperammonemia cause urea cycle disorder , lysinuric protein intolerance , mitochondrial disorder , congenital lactic academia , fatty acid oxidation defect primary liver disease Subjects require peripherally insert central catheter ( PICC ) blood draw may need moderately sedate excluded Subjects hemoglobin &lt; 9 g/dl</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hyperammonemia</keyword>
</DOC>